To the editor
Serum sickness-like reactions (SSLR) to β-lactams are non-immediate drug
reactions affecting primarily children, mainly during the first 2 years
of life.(1) This entity has been poorly investigated and its prevalence
remains unknown.(2) SSLR is characterized by the presence of cutaneous
signs and symptoms associated with arthritis/arthralgia. The skin
manifestations might include erythematous macular, maculopapular
exanthemas and urticaria which can evolve to purple lesions (figure 1).
Fever is a common symptom present in as much as 40% of children.(3)
Symptoms usually start 7 to 21 days after initial drug exposure.(4)
Cefaclor was the most commonly incriminated drug, but other β-lactams,
anti-inflammatory, anti-convulsants and other compounds, including
biologicals and vaccines, have been reported.(5)
Although SSLR is a self-limiting disease, it is often considered as a
severe drug reaction and strict avoidance of the offending and
chemically related drugs without an allergy work-up is a common
recommendation in clinical practice.(6) However, other causes, in
particular viral or Streptococcus infections, have been
reported. Since no clinical or laboratory findings differentiate SSLR
from infectious exanthemas, a complete allergic study is necessary to
confirm or exclude a drug reaction. Drug provocation test (DPT) without
prior skin testing is a procedure that has been reported to be secure in
children with benign exanthema/urticaria induced by drugs.(7)
Children with a history suggestive of SSLR to a β-lactam and an allergic
study were included in 4 tertiary European pediatric allergy centers
(Belgrade, Florence, Porto and Madrid) between 2008 and 2023. Skin
involvement, including macular or maculopapular exanthems and urticaria,
associated with arthritis/arthralgia were required for the diagnosis,
with fever being an additional symptom. DPT to the culprit drug without
prior skin testing was proposed to all parents. In all centers, an
initial graded dose followed by a prolonged DPT was performed (up to 5
days in Serbia and Italy, up to 7 days in Portugal and Spain). Data on
clinical manifestations and the results of the allergic work-up,
including DPT to culprit or an alternative β-lactam, were analyzed.
A total of 218 children were evaluated between January 2008 and May
2023. The demographic data as well as further characteristics are
summarized in Table 1. Two hundred and twelve (97.3%) children
underwent a DPT (table 2). It was not performed in six cases due to
parental refusal. In 187 (88.2%) children DPT was performed with the
culprit drug, and in 25 (11.8%)
with an alternative β-lactam. The median latency between the index
reaction and DTP was 4.5 (IQR 10).
Twenty (10.7%) cases had a positive DPT with the culprit drug. From
these, 16 (76.2%) had exanthema/urticaria and arthritis, 3 (14.3%)
isolated exanthema/urticaria, 1 (4.8%) exanthema/urticaria, angioedema,
and arthritis and 1 (4.8%) exanthema/urticaria, arthritis, and fever.
Only one child reacted to an alternative β-lactam with only
exanthema/urticaria. None reacted to the first doses given during the
graded challenge and no immediate reactivity was observed with
subsequent doses. No severe reactions were observed, being all resolved
with oral treatment. The presence of fever combined with skin symptoms
and arthritis/arthralgia during the index reaction was not associated
with a higher risk for a positive DPT (p=0.36). No children reacted on
the first day of challenge.
The diagnosis of SSLR is based on clinical symptoms as no specific
biomarkers are currently available and diagnostic procedures are not
well established. The absence of definite criteria for SSLR makes the
diagnosis difficult and can lead to overdiagnosis of this entity.
Indeed, distinguishing it from urticaria with angioedema, particularly
localized at the joints might be difficult. In clinical practice, most
of the patients developing symptoms of SSLR are considered to have a
severe drug allergy (DA) and avoidance of the incriminated drug is
recommended in the future. However, our results confirm that the
clinical history and physical examination are not sufficient for the
diagnosis of a DA in children with SSLR, highlighting the importance of
an allergic study, particularly a diagnostic DPT. In fact, only a small
proportion (10.7%) of the children included had a positive DPT to the
culprit drug and no severe reaction occur in any DPT performed, pointing
out that this procedure without prior skin testing is safe in children
with a history of SSLR.
As for benign skin manifestations, the high rate of negative DPT might
be explained by the high incidence of infections, viral in particular,
in the pediatric population, that mimic DA.(7,8) In fact, infections can
cause skin exanthemas, angioedema, fever and arthralgia. (4,7) Viruses
have also been shown to play an important role as co-factors in DA, not
reproducible upon further exposures to the drug. This has been shown for
severe cutaneous adverse reactions (SCAR), but also in patients
developing a skin rash while under aminopenicillin treatment with an
underlying Epstein-Barr virus (EBV) infection.(9,10) In our study,
serologic study was performed in 113 children (51.6%) showing during
the index reaction a positive IgM for adenovirus in 42.4%, forMycoplasma Pneumoniae in 39.4% and in one case to 3 different
viruses (EBV, Cytomegalovirus and Human Herpes Virus-6).
The protocol used for DPT varies between countries and centers and is
generally not standardized. In a recent study, Delli Colli et al.
performed a DPT in 75 children with a history of SSLR to β-lactams and
2.7% of them had an immediate reaction during a graded 1-day
challenge.(3) In our study, none of the 21 children with a positive DPT
experienced an immediate reaction. Based on our findings and the fact
that no severe immediate reactions have been observed in both studies,
we suggest that DPT with an initial full therapeutic dose can be
considered useful and secure in children with a clinical history
suggestive for SSLR. A graded challenge, that is more time consuming and
associated with higher medical costs, could be avoided.
In the study by Delli-Colli et al., 25% of children with a negative
1-day challenge experienced a mild reaction on subsequent curses of the
culprit drug suggesting that a 1-day challenge might be insufficient to
diagnose DA.(3) In our study, a prolonged protocol led to a higher DPT
positivity rate (10.7% versus 6.7% in study by the Delli Colli et al.)
and might indicate a higher sensitivity of our procedure. Most children
with a positive DPT reacted at day 5 and based on these, a 5-days
protocol seems appropriate to identify children with an underlying DA.
Two children in Portugal undergoing a 7-days DPT did react after the
5th day. However, increasing the length of DPT to
identify only few more patients who develop a rather benign reaction is
always debatable.
The latency between the index reaction and the DPT still needs to be
determined. Although the mean interval was 12.6 months (SD 24.8) when
considering all centers together, the mean interval in the Serbian
population was 5.3 (SD 8.6) months without a significative difference in
DPT positivity, suggesting that DPT might be performed as soon as 6
months after index reaction.
Our data suggest that DPT with an initial full dose is a safe procedure
in children with a history of SSLR and that a prolonged DPT seems
necessary to increase its sensitivity.